Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Mineralys is a biopharmaceutical company developing lorundrostat, a proprietary, orally administered aldosterone synthase inhibitor (ASI) for cardiorenal conditions, primarily hypertension. The company has no approved products and has not generated revenue. It is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(154,651) | $(177,810) |
| Research & Development Expenses | $(132,009) | $(168,581) |
| General & Administrative Expenses | $(38,595) | $(23,822) |
| Cash, Cash Equivalents, and Investments | $656,600 | $198,187 |
| Accumulated Deficit | $(457,169) | $(302,518) |
| Net Cash Used in Operating Activities | $(142,416) | $(166,314) |
| Net Cash Provided by Financing Activities | $590,999 | $116,142 |
Note: The filing text does not provide specific margin or debt figures as the company has no revenue and no long-term debt obligations listed on the balance sheet.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $23.2 million (13%) compared to 2024, primarily driven by a $36.6 million reduction in R&D expenses.
- R&D Expense Decline: R&D expenses dropped significantly due to the conclusion of the pivotal clinical program (Launch-HTN and Advance-HTN) in the second quarter of 2025, offset partially by increased compensation and manufacturing costs.
- G&A Expense Increase: General and administrative expenses increased by $14.8 million, driven by higher compensation costs and professional fees.
- Liquidity Expansion: Cash, cash equivalents, and investments increased from approximately $198 million in 2024 to $656.6 million in 2025. This was fueled by $578 million in net proceeds from equity financings (two public offerings and ATM sales) during 2025.
- Investing Activities: Net cash used in investing activities shifted from a positive $115 million in 2024 to a negative $390 million in 2025, reflecting increased purchases of marketable securities.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Regulatory Status: The company submitted a New Drug Application (NDA) to the FDA in December 2025 for lorundrostat to treat hypertension. The FDA accepted the submission with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.
- Clinical Highlights:
- Launch-HTN (Phase 3): Met primary endpoint with a statistically significant placebo-adjusted reduction in systolic blood pressure (11.6 mmHg at Week 12).
- Explore-CKD (Phase 2): Demonstrated significant reduction in systolic BP and urinary albumin creatinine ratio (UACR) in patients with hypertension and chronic kidney disease.
- Explore-OSA (Phase 2): Did not meet the primary endpoint for apnea-hypopnea index (AHI) but showed clinically meaningful blood pressure reductions.
- Liquidity: Management believes current cash resources are sufficient to fund operations for at least 12 months from the filing date.
Risks and Contingencies
- Single Product Dependence: The business relies entirely on the success of lorundrostat. Failure to obtain approval or commercialize the drug would materially harm the company.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to fund commercialization and future development.
- Third-Party Reliance: The company relies on Tanabe Pharma Corporation for intellectual property rights and third-party manufacturers for production. Termination of the Tanabe license or manufacturing failures would be catastrophic.
- Regulatory Uncertainty: Approval is not guaranteed. The FDA may issue a Complete Response Letter requiring additional data or trials.
Investor Verification Checklist
- NDA Acceptance: Verify the FDA's official acceptance of the December 2025 NDA and the confirmed PDUFA date of December 22, 2026.
- Cash Runway: Monitor quarterly cash burn rates to confirm the 12-month liquidity runway remains valid given the high cost of pre-commercialization activities.
- Tanabe License Obligations: Review the specific commercial milestone payments (up to $155 million) and royalty rates (mid-single digits to 10%) owed to Tanabe Pharma upon approval and sales.
- ATM Facility: Track the utilization of the $300 million At-The-Market (ATM) equity offering facility, noting $207.5 million remained available as of December 31, 2025.
- Hyperkalemia Safety Data: Review long-term safety data regarding hyperkalemia (elevated potassium) as a potential side effect, which was a key safety monitoring point in clinical trials.